The Hong Kong-based provider of pain relief services using traditional Chinese principles aims to raise about $7.2 million through its U.S. listing, valuing it at up to $200 millionKey Takeaways:Anew Health has filed for a U.S. IPO, aiming to sell investors on its use of techniques based on traditional Chinese medicine principles to treat painThe Hong Kong-based company plans to raise about $7.2 million, about half earmarked for expanding both at home and in other markets with big Asian populationsTradition ...

Revenue miss - 1H25 revenue decreased by 4.8% (-7.5% vs. GSe), and net profits also missed at Rmb1,442mn (-16.2% yoy, -16.2% vs. GSe). Its core revenue (hepatic disease medication) still grew by 9.7% yoy despite weak consumption power, while total revenue missed mainly due to revenue decrease from distribution (-13% yoy) and cosmetics & personal goods (-17% yoy). Earnings miss - 1H25 net profits also missed, attributed to higher raw material cost in 1H25, resulting in GPM of hepatic disease medication decre ...

Hello everyone, my name is Renley. Today I want to talk about the collision between artificial intelligence with traditional Chinese medicine. What if I told you that in the climate right now an AI is analyzing tone coding with picture perfect precision.Can you imagine the spark when silver needles with horrible medicine with uh artificial intelligence. This is the age where old wisdom meets tomorrow's tools and it's happening right around us. My grandma has old medicine chest at home.The herbs and fork rem ...

From koji-making to pharmaceutical preparation, from the differentiation of yin and yang to the transformation of the five elements, traditional Chinese medicine (TCM) and Chinese culture have been influencing generations of Chinese people. With accessible principles and stories, Dr. WEN Junkai painted a vivid picture of the endless vitality of nature and the harmonious transformation of all things in the universe, along with their philosophical underpinnings. He also affirmed the necessity of integrating t ...

Singapore will gradually integrate more traditional Chinese medicine treatments into its public healthcare system to explore how such therapies could complement Western ones. https://t.co/wSufeObJeZ ...

Core Viewpoint - Regencell Bioscience Holdings Ltd., a Hong Kong-based biotech startup, has experienced an extraordinary stock price increase of over 59,000% in 2025, reaching a market value of nearly $30 billion despite having no reported revenue [1][3]. Company Overview - Regencell is focused on developing traditional Chinese herbal treatments for childhood ADHD and autism, in collaboration with TCM practitioner Sik-Kee Au, who is also the CEO's father [3]. - The company has not generated any revenue or received regulatory approval for its products, and its latest annual report indicates net losses of $4.36 million and $6.06 million for the fiscal years ending June 2024 and 2023, respectively [3][4]. Stock Performance - Following a 38-for-1 stock split announced in June, Regencell's stock surged by over 280% on a single day [1]. - The company's market valuation is now comparable to major firms like Lululemon Athletica, Inc. and exceeds that of Super Micro Computer, Inc. and Reddit, Inc. [2]. Shareholder Structure - The CEO of Regencell holds 86% of the company's outstanding shares, which may be influencing the stock price dynamics [4]. Market Sentiment - Regencell has become a trending stock on platforms like Yahoo Finance and Stocktwits, with mixed social media commentary. Some retail investors are enthusiastic about the stock's volatility, while others express skepticism, likening its trading behavior to that of meme coins [5]. - As of Tuesday, Regencell shares were up 23% at $73.80 [5].

Core Insights - Regencell's stock has experienced a dramatic increase, with shares rising over 280% in a single day, following a 38-for-1 stock split [2][4] - The company, which focuses on traditional Chinese herb treatments for ADHD and autism, has seen its market capitalization reach approximately $29.7 billion [1][2] - Despite the stock surge, Regencell has not generated any revenue and has incurred significant net losses in recent fiscal years [9][10] Company Overview - Regencell, founded in 2014, is a Hong Kong-based bioscience company that trades on Nasdaq under the ticker 'RGC' since 2021 [1][2] - The CEO, Yat-Gai Au, controls 86.24% of the total shares outstanding [1] - The company develops proprietary Traditional Chinese Medicine (TCM) formulas aimed at treating ADHD and Autism Spectrum Disorders (ASD) [7][8] Financial Performance - Regencell reported total net losses of $4.36 million and $6.06 million for the fiscal years ended June 2024 and 2023, respectively [9] - The company has not generated any revenue from its TCM formula candidates nor applied for regulatory approvals [10] Market Activity - The stock's volatility is notable, with significant one-day price swings, including a 30% increase followed by a 30% decrease on consecutive trading days [6] - Regencell's market value is now comparable to established companies like Lululemon and exceeds that of Super Micro Computer and Fifth Third Bancorp [3] Product Development - Regencell's TCM formula candidates are designed to address varying severities of ADHD and ASD, utilizing natural ingredients [8] - The company has conducted limited efficacy trials, with a recent case study indicating symptom improvement in 28 patients over three months [11] Industry Context - The surge in Regencell's stock coincides with a growing interest in alternative medicines, particularly following the appointment of Robert F. Kennedy Jr. as Secretary of the U.S. Department of Health and Human Services [5] - Regencell's stock has drawn comparisons to other speculative stocks, such as AMTD Digital, which also saw significant price increases without substantial fundamentals [3]